Dalian Wanchunbulin Pharmaceuticals

Dalian Wanchunbulin Pharmaceuticals is a clinical-stage biopharmaceutical company based in China and a majority-owned subsidiary of BeyondSpring. The company is primarily focused on the clinical development and commercialization of innovative cancer therapies in the Greater China region, holding the exclusive rights to BeyondSpring's lead asset, Plinabulin. Plinabulin is a first-in-class, small-molecule GEF-H1 agonist designed to prevent chemotherapy-induced neutropenia (CIN) and treat various cancers, including non-small cell lung cancer (NSCLC). Dalian Wanchunbulin has advanced Plinabulin through late-stage clinical trials and submitted New Drug Applications (NDAs) to China's National Medical Products Administration (NMPA).